Integral Health Asset Management, LLC Akero Therapeutics, Inc. Transaction History

Integral Health Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $1.24 Million - $1.57 Million	30,000 Added 42.86%	100,000 $5.06 Million
Q4 2022 Feb 13, 2023	SELL	$33.44 - $54.8 $5.35 Million - $8.77 Million	-160,000 Reduced 69.57%	70,000 $3.84 Million
Q3 2022 Nov 14, 2022	SELL	$10.15 - $34.05 $589,288 - $1.98 Million	-58,058 Reduced 20.15%	230,000 $7.83 Million
Q2 2022 Aug 03, 2022	BUY	$8.0 - $15.01 $704,464 - $1.32 Million	88,058 Added 44.03%	288,058 $2.72 Million
Q1 2022 May 12, 2022	BUY	$12.97 - $22.26 $1.49 Million - $2.56 Million	115,000 Added 135.29%	200,000 $2.84 Million
Q2 2021 Aug 30, 2021	SELL	$24.81 - $32.35 $2.11 Million - $2.75 Million	-85,000 Reduced 50.0%	85,000 $2.11 Million
Q2 2021 Aug 13, 2021	BUY	$24.81 - $32.35 $2.11 Million - $2.75 Million	85,000 Added 100.0%	170,000 $4.22 Million
Q3 2020 Nov 16, 2020	BUY	$30.79 - $39.92 $2.62 Million - $3.39 Million	85,000 New	85,000 $2.62 Million
Q2 2020 Aug 14, 2020	SELL	$19.25 - $26.76 $1.16 Million - $1.61 Million	-60,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$12.8 - $27.05 $768,000 - $1.62 Million	60,000 New	60,000 $1.27 Million

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.36B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.